The investment seeks investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Health Care Select Sector Index... Show more
The Health Care Select Sector SPDR Fund (XLV) tracks the S&P Health Care Select Sector Index, providing targeted exposure to U.S. large-cap healthcare companies within the S&P 500. Its strategy focuses on market-cap-weighted holdings across pharmaceuticals, healthcare equipment and supplies, providers and services, and biotechnology. Top holdings typically feature Eli Lilly, Johnson & Johnson, and other leading firms, with the top 10 representing over 60% of assets. Geographic allocation centers on the United States, with negligible international exposure. This structure drives performance through sector-specific fundamentals such as innovation pipelines, reimbursement trends, and demographic tailwinds, positioning the ETF for sensitivity to healthcare policy and economic cycles rather than broad market movements.
Interest rate decisions by the Federal Reserve could influence borrowing costs for healthcare companies and investor appetite for growth-oriented subsectors. Inflation trends affect input costs for providers and equipment manufacturers, potentially pressuring margins. Economic growth expectations influence elective procedures and overall healthcare utilization. Sector growth outlook benefits from ongoing advancements in GLP-1 therapies and precision medicine. Policy or regulatory changes, including drug pricing reforms and CMS rate adjustments, represent material risks or opportunities. Earnings outlook for major holdings such as Eli Lilly and UnitedHealth Group may highlight pipeline progress or utilization patterns. ETF inflows and outflows trends provide signals of institutional positioning ahead of these developments.
Broader macroeconomic forces connect directly to XLV’s underlying assets. Lower or stable interest rates could support higher valuations for healthcare equities by reducing discount rates on future cash flows. Persistent inflation may elevate operating expenses for hospitals and insurers. Economic growth expectations drive demand for medical services and pharmaceuticals. Equity market trends influence capital flows into defensive sectors like healthcare during periods of uncertainty. Global markets and currency movements have limited direct impact given the domestic focus, though cross-border M&A activity could introduce volatility. Bond market outlook and commodity cycles affect cost structures in medical supplies and pharmaceuticals.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. Trend Prediction Engine
Long-term sector growth trends remain anchored in demographic shifts, including an aging U.S. population and rising chronic disease incidence, which support sustained demand for healthcare services and products. Technology adoption, particularly in artificial intelligence-driven drug discovery and digital health platforms, could enhance productivity and expand addressable markets for major holdings. Economic cycles may introduce periodic volatility, yet healthcare’s defensive characteristics provide relative stability. Market structure changes, such as continued consolidation through M&A, could reshape competitive dynamics. Interest rate cycles influence capital allocation toward innovation-intensive segments, while global investment trends favor sectors with resilient fundamentals. The long-term outlook for the underlying index centers on these secular themes rather than short-term fluctuations.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Category Health
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CRCG | 15.13 | 1.41 | +10.28% |
| Leverage Shares 2X Long CRCL Daily ETF | |||
| EFAV | 94.63 | 0.68 | +0.72% |
| iShares MSCI EAFE Min Vol Factor ETF | |||
| FNGS | 79.04 | 0.40 | +0.51% |
| MicroSectors™ FANG+™ ETN | |||
| PMAP | 27.50 | N/A | N/A |
| PGIM S&P 500 Max Buffer ETF - April | |||
| XOMO | 11.40 | -0.05 | -0.44% |
| YieldMax XOM Option Income Strategy ETF | |||
A.I.dvisor indicates that over the last year, XLV has been closely correlated with IYH. These tickers have moved in lockstep 99% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then IYH could also see price increases.
| Ticker / NAME | Correlation To XLV | 1D Price Change % | ||
|---|---|---|---|---|
| XLV | 100% | +1.29% | ||
| IYH - XLV | 99% Closely correlated | +1.25% | ||
| FHLC - XLV | 99% Closely correlated | +1.22% | ||
| VHT - XLV | 98% Closely correlated | +1.24% | ||
| IXJ - XLV | 97% Closely correlated | +1.12% | ||
| RSPH - XLV | 88% Closely correlated | +1.45% | ||
More | ||||
The Moving Average Convergence Divergence (MACD) for XLV turned positive on August 10, 2026. Looking at past instances where XLV's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 24, 2026. You may want to consider a long position or call options on XLV as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in of 324 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 267 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for XLV moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
XLV broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.